Revascular Bio addresses
the magical power
of blood vessels



Takakura Lab has published the paper in terms of endothelial stem cells 



Maximize the vascular potential and deliver it to the lives of patients around the world



To be the technology-driven leading cell therapy company, bringing transformational and effective therapies addressing intractable diseases.




Disorders of "blood vessels" that spread throughout the body cause various diseases, and there is still no effective treatment for disorders of microscopic blood vessels. We aim to solve these diseases by developing cell therapy using vascular endothelial stem cells.

LINETherapeutic concept

Therapeutic concept

Target Diseases

Chronic wounds (intractable skin ulcers), severe lower limb ischemia, cerebrovascular dementia, breast reconstruction therapy, hemophilia, lysosomal diseases

Cell Therapies

"Angiogenesis therapy" recovers micro-blood flow disorders by transplanting vascular endothelial stem cells, "angiocrine therapy" permanently supplies proteins damaged by gene-deficient diseases and utilizes gene editing technology. The "Protein Production/Secretion Platform" will enable the realization of various groundbreaking treatments

LINETreatment model

Treatment model

LINECurrent Pipeline

Current Pipeline



Collaborator : Nobuyuki Takakura, M.D., Ph.D.

Professor, Research Institute for Microbial Diseases, Osaka University

Endothelial cells, which form the lumen of blood vessels, serve as an interface between tissue cells and blood flow within the body, and not only maintain homeostasis by supplying humoral signals, but also play a central role in the coordination mechanism of the whole body through organ connections. We have shown that the stem cell system within the blood vessel itself is essential for this intravascular turnover of vascular endothelial cells, and that by controlling these vascular endothelial stem cells, unprecedented organ reconstruction becomes possible. By utilizing the role of vascular endothelial stem cells as a control tower for the general state of the body, we will take on the challenge of developing new treatments for genetic deficiency diseases for which there are currently no radical treatments and for suppressing the growth of cancer over the long term.


Endothelial cells (ECs) are designated as CD31+CD45- cells (upper left). We found that CD157positive ECs are EC stem cells in the pre-existing blood vessels in all argans. In liver,CD157+CD200+ ECs represent stemness (lower left) and they have potential to regenerate sustainable blood vessels (sinusoids) in liver injury model (right). In other organs, CD157+ ECs show revascularization ability in many disease models including such as ischemic diseases and genetic diseases.

We have discovered that vascular endothelial stem cells exist in pre-existing blood vessels, which maintain organ-specific vascular structures and functions, and rapidly rebuild blood vessels when damaged. (Wakabayashi et al. Cell Stem Cell 2018, Naito et al. Nature Protocol 2020). In recent years, genetic analysis of tissue cells of various organs using single cell RNA sequencing has been actively conducted. As a result, gene expression specific to arteries, veins, and capillaries has been observed among vascular endothelial cells, moreover, it has been revealed that there are endothelial cells having potential to show tissue/organ specific function. It is thought that such heterogeneity of vascular endothelial cells is maintained by vascular endothelial stem cells. Recently, we have clarified the development and age-related changes of vascular endothelial stem cells (Rahmawati FN et al. Stem Cell Research & Therapy 2023, Shimizu et a. Angiogenesis 2023). Based on utilizing such results from basic research, we challenge to manipulate efficient and sustainable vascular regeneration through vascular endothelial stem cell transplantation.




Kazuo Omori, M.D., Ph.D., MBAPresident & Chief Executive Officer, Co-Founder
Fumio Nishikaku, Ph.D.Chief Operating Officer, Co-Founder


Kazuo OmoriBoard Member
Fumio NishikakuBoard Member
Yuki TagaBoard Member
Masahiro Motokawa, C.P.A.Audit & Supervisory Board Member


CEO:Kazuo Omori, M.D,, Ph.D.

CEO: Kazuo Omori, M.D., Ph.D., MBA

Revascular Bio is a startup with the mission to deliver endothelial stem cells as pharmaceuticals to enhance the lives of patients.

Blood vessels” are the largest organs, extending throughout the body. Their wide-ranging functions, including delivering oxygen and nutrients, and secreting proteins are essential for life activities and maintaining health. In order for these blood vessel functions to be performed appropriately, blood vessels are constantly being generated and maintained in the body.

Our core technology, “vascular endothelial stem cells”, are play the leading role in such dynamic changes in blood vessels in living organisms. A Co-founder Professor Takakura of Osaka University was the first in the world to discover these cells, and has since proven that transplanting these cells would have revolutionary efficacy against various vascular diseases.
Although there are many vascular diseases, effective treatments have been notably lacking especially for microvascular disorders, and as a result, numerous patients, their families, and medical professionals continue to endure their suffering.
In order to revolutionize this current situation, we are fully committed to developing vascular endothelial stem cell technology as a new cell medicine and delivering it to patients' lives.
To illuminate the light of hope for tomorrow for the patients around the world.



Basic Information

  • Name

    Revascular Bio Co., Ltd.

  • Establishment

    September 8, 2022

  • Representative

    Kazuo Omori, Representative Director, President and CEO

  • Fiscal year

    April 1 to March 31

  • Employees

    5 (as of November 10, 2023)

  • Head Office

    3-1 Yamadaoka, Suita, Osaka 565-0871





Content of inquiry*